Bruce Booth is a partner and focuses on the discovery and development of novel medicines and therapeutic platforms.

Bruce is currently chairman of Arkuda Therapeutics, Hotspot Therapeutics, Kymera Therapeutics (NASDAQ: KYMR), Matchpoint Therapeutics, Nimbus Therapeutics, and Vigil Neuroscience (NASDAQ: VIGL). He also serves on the boards of Lifordi Immunotherapeutics and Sionna Therapeutics, and several seed stage companies. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Lysosomal Therapeutics (acquired by Bial), Padlock Therapeutics (acquired by BMS), Prestwick (acquired by Biovail), Rodin Therapeutics (acquired by Alkermes), Stromedix (acquired by Biogen), and a number of other ventures.

Bruce serves or has served as an advisor in various capacities to Takeda, UCB, the Gates Foundation, Dana Farber’s Binney Street Capital, and the Penn State Research Foundation. He also serves on the board of New England Disabled Sports, a charity dedicated to adaptive sports. Bruce blogs about biotech and venture capital topics at LifeSciVC.com.

Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a D.Phil. (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from The Pennsylvania State University.

Bruce enjoys running, skiing, hiking, and fishing. He lives in Wellesley, MA and has three wonderful kids.